Physician profile
Kumar Gaurav
NPI 1467617902
$12,686.34
in general payments reported to CMS, 2019-2025
14 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.90 · 2020: $3,071 · 2021: $813 · 2022: $2,886 · 2023: $43.96 · 2024: $5,596 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Travel and Lodging: $997 · Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Travel and Lodging | $996.51 |
| Food and Beverage | $368.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,037.97 | 2022-2024 | |
| Pinnacle Biologics, INC | $2,838.81 | 2020 | |
| Ethicon INC. | $2,310.78 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $106.25 | 2025 | Purified Cortrophin Gel |
| Pulmonx Corporation | $82.16 | 2020 | |
| Merck Sharp & Dohme LLC | $68.09 | 2024-2025 | Keytruda, Lynparza |
| Olympus America INC. | $50.90 | 2019 | |
| Daiichi Sankyo INC. | $50.58 | 2024-2025 | Enhertu |
| Lilly USA, LLC | $49.25 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $21.97 | 2025 | |
| Inari Medical, INC. | $20.72 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alexion Pharmaceuticals, INC. | $17.46 | 2025 | Ultomiris |
| Genentech USA, INC. | $17.08 | 2025 | Itovebi |
| Seagen INC. | $14.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Gaurav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.